Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 555K 517K 475K 896K 60.98M 910K 6.09M 2.39M 30.36M 2.4M 2.35M 102M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 16.92M 15.75M 14.46M 27.31M 1.86B 27.73M 186M 72.87M 925M 73.11M 71.5M 3.1B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

20-06-11	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
20-05-29	Achaogen, Inc. Went Out of Business	CI
20-05-29	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
20-04-22	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-04-21	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
20-03-30	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
20-01-08	Motion for Asset Sale Approved for Achaogen, Inc.	CI
19-12-29	Motion for Asset Sale Filed by Achaogen, Inc.	CI
19-09-24	Final DIP Financing Approved for Achaogen, Inc.	CI
19-08-29	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
19-08-13	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
19-07-29	Achaogen, Inc. Announces Management Changes	CI
19-07-23	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.71M 9.04M 8.3M 15.68M 1.07B 15.92M 107M 41.83M 531M 41.97M 41.05M 1.78B	8.73M 7.59M 7.06M 6.48M 12.24M 833M 12.43M 83.24M 32.67M 415M 32.78M 32.06M 1.39B
Net income	-126M -109M -102M -93.32M -176M -11.99B -179M -1.2B -470M -5.97B -472M -461M -20.02B	-187M -162M -151M -139M -262M -17.8B -266M -1.78B -698M -8.86B -700M -685M -29.72B
Net Debt	-143M -124M -116M -106M -200M -13.64B -203M -1.36B -535M -6.79B -536M -525M -22.76B	18.83M 16.37M 15.23M 13.99M 26.41M 1.8B 26.82M 180M 70.48M 895M 70.71M 69.16M 3B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news : Achaogen

Financials

Company Profile